SANOFI AVENTIS US Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SANOFI AVENTIS US, and what generic alternatives to SANOFI AVENTIS US drugs are available?
SANOFI AVENTIS US has one hundred and twenty-two approved drugs.
There are ten US patents protecting SANOFI AVENTIS US drugs.
There are two hundred and seventeen patent family members on SANOFI AVENTIS US drugs in fifty-two countries and one hundred and fifteen supplementary protection certificates in nineteen countries.
Summary for SANOFI AVENTIS US
| International Patents: | 217 |
| US Patents: | 10 |
| Tradenames: | 97 |
| Ingredients: | 85 |
| NDAs: | 122 |
Drugs and US Patents for SANOFI AVENTIS US
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | ISUPREL | isoproterenol hydrochloride | SOLUTION;INHALATION | 006327-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Sanofi Aventis Us | GLYBURIDE (MICRONIZED) | glyburide | TABLET;ORAL | 020055-003 | Mar 8, 2000 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Sanofi Aventis Us | AUBAGIO | teriflunomide | TABLET;ORAL | 202992-001 | Sep 12, 2012 | AB | RX | Yes | No | 9,186,346*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Sanofi Aventis Us | SLO-BID | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 087893-001 | Jan 31, 1985 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SANOFI AVENTIS US
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | KETEK | telithromycin | TABLET;ORAL | 021144-001 | Apr 1, 2004 | D459798 | ⤷ Subscribe |
| Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-002 | Jan 30, 1998 | 4,692,435 | ⤷ Subscribe |
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | SUSPENSION;ORAL | 017430-001 | Approved Prior to Jan 1, 1982 | 4,105,659 | ⤷ Subscribe |
| Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-005 | Mar 27, 1998 | 4,692,435 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANOFI AVENTIS US drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 100 mg/mL, 3 mL vials | ➤ Subscribe | 2006-12-07 |
| ➤ Subscribe | Extended-release Tablets | 12.5 mg | ➤ Subscribe | 2006-01-19 |
| ➤ Subscribe | Tablets | 150 mg/12.5 mg and 300 mg/12.5 mg | ➤ Subscribe | 2004-11-10 |
| ➤ Subscribe | Tablets | 75 mg, 150 mg and 300 mg | ➤ Subscribe | 2004-05-25 |
| ➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-03-04 |
| ➤ Subscribe | Injection | 40 mg/mL, 0.5 mL and 2 mL vials | ➤ Subscribe | 2009-06-30 |
| ➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2007-02-09 |
| ➤ Subscribe | Injection | 5 mg/mL, 40 mL vial | ➤ Subscribe | 2011-03-23 |
| ➤ Subscribe | Extended-release Tablets | 6.25 mg | ➤ Subscribe | 2006-02-24 |
| ➤ Subscribe | Tablets | 7 mg and 14 mg | ➤ Subscribe | 2016-09-12 |
| ➤ Subscribe | Tablets | 300 mg/25 mg | ➤ Subscribe | 2006-06-06 |
| ➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2013-07-01 |
| ➤ Subscribe | Injection | 5 mg/mL, 10 mL and 20 mL vials | ➤ Subscribe | 2007-02-09 |
| ➤ Subscribe | Injection | 200 mg/40 mL | ➤ Subscribe | 2007-07-16 |
International Patents for SANOFI AVENTIS US Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2011518785 | ⤷ Subscribe |
| Peru | 20121478 | ⤷ Subscribe |
| European Patent Office | 1381356 | ⤷ Subscribe |
| Canada | 2708489 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for SANOFI AVENTIS US Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1667986 | SPC/GB13/042 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: CABAZITAXEL IN THE FORM OF THE ACETONE SOLVATE; REGISTERED: UK EU/1/11/676/001 20110317 |
| 0443983 | C00443983/03 | Switzerland | ⤷ Subscribe | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
| 0454511 | SPC/GB99/008 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
| 2344130 | 2017/038 | Ireland | ⤷ Subscribe | PRODUCT NAME: OZENOXACIN; NAT REGISTRATION NO/DATE: PA1744/003/001 20170616; FIRST REGISTRATION NO/DATE: ES/H/414/01/DC 20170519 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
